Navigation Links
Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
Date:9/10/2009

imaging.cancer.gov/clinicaltrials/imaging/" target="_new">RECIST criteria. No patient in any dose group exhibited any signs of acute neurotoxicity, which is a major adverse side-effect of the approved DACH platinum, Eloxatin, and ProLindac was well tolerated overall.

The recent Phase 2 recurrent ovarian study explored three different dose levels and two dosing regimens of ProLindac as a monotherapy treatment for advanced ovarian cancer, to provide data on the monotherapy anticancer activity and safety of ProLindac. Of patients eligible for evaluation according to standard RECIST criteria, clinically-meaningful disease stabilization was achieved in 42% of all patients, and 66% of all patients in the higher dose groups. Sustained and significant reductions in Ca-125, the established specific serum marker for ovarian cancer, were also observed in several patients.

"Access is extremely pleased with the clinical progress to date, and look forward to initiation of clinical trials looking at ProLindac in combination with commonly used chemotherapies," stated Jeffrey Davis, President & CEO. "Our partners in the Far East hosted Access together with key opinion leaders in oncology indications to discuss various potential protocol options, and hope to start enrolling patients in up to three combination trials by the end of the year, depending upon regulatory approvals of the trial protocols and certain other matters."

About ProLindac(TM):

ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion.
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference
2. NuAire Laboratory Economic Stimulus Package -- Free Accessories or Factory Options
3. One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions
4. Understanding Managed Markets: Effective Market Research Structures & Activities to Maximize Payer Access & Insights
5. Access Pharmaceuticals CEO Interviewed on Financial Website
6. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
7. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
8. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
9. Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China
10. Cyprotex Launches Cloe(R) Gateway, its Secure web Portal for Access to Cyprotex Services Including an Enhanced Version of Cloe(R) PK.
11. Ochsner and LSUHSC Partner to Provide Better Local Access to Comprehensive Cancer Care

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... , MALVERN, Pa. and WALTHAM, Mass., Nov. 19 /P...d Decision Resources find that the leading driver ... Europe is broad-spectrum activity against gram-po...iety of organisms that can cause nosocomial pneumo... look primarily for agents that provide appropriat...
(Date:11/19/2009)... World,s Top Gene Synthesis Compa...(IGSC) to Coordinate Best Practices in Risk Reduct...of Worldwide Gene Synthesis Capacity , ... the world’s leading gene synthesis companie... common screening protocol to promote biosecurity ...
(Date:11/18/2009)...ist at the National Institute of Standards and Tec...e, inexpensive method for detecting and measuring ...oxins, invisible spoilage in food or pesticides di...method is more sensitive than conventional techniq... are polarlike water molecules, having distinct el...
(Date:11/18/2009)..., RICHMOND, Calif., Nov. 18 /PRNewswire-FirstCal...nnounced today that data from the University of Pe...tudy of Sangamo,s zinc finger nuclease (ZFN) based...y and prematurely disclosed on the internet. ,,...iversity of Pennsylvania School of Medicine from a...
Breaking Biology Technology:Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4Prototype NIST method detects and measures elusive hazards 2Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS 2
...Summary: Genmab Will Receive a Milestone Payment o...hievement of Positive Results in the Phase III CLL...N, August 21 Genmab A/S (OMX: GEN),announced toda...b,(HuMax-CD20(R)) under the terms of its collabora...nt of approximately DKK 232.7 million,(approximate...
...SAN DIEGO, Aug. 21 Vical Incorporated,(Nasdaq: V...rimate studies,of a Vaxfectin(R)-formulated DNA va...f Clinical and Vaccine Immunology(1), offer a prom...cine to address an unmet need,for human infants. V...ase 1,trial results for the company,s H5N1 pandemi...
...REINACH, Switzerland, August 21 Arpida Ltd.,(SWX:... Agency (EMEA) has,accepted for review its Marketi... iclaprim. Arpida is seeking approval of intraveno...t of complicated Skin and Soft Tissue,Infections (...didate with,potent bactericidal (killing) activity...
Other Biology Technology:Genmab Reaches Fifth Milestone in Ofatumumab Collaboration 2Genmab Reaches Fifth Milestone in Ofatumumab Collaboration 3Vaxfectin(R)-formulated Measles DNA Vaccine Could Address Unmet Need for Infants 2Vaxfectin(R)-formulated Measles DNA Vaccine Could Address Unmet Need for Infants 3Vaxfectin(R)-formulated Measles DNA Vaccine Could Address Unmet Need for Infants 4Vaxfectin(R)-formulated Measles DNA Vaccine Could Address Unmet Need for Infants 5Arpida's iclaprim MAA Accepted for Review by EMEA 2Arpida's iclaprim MAA Accepted for Review by EMEA 3
(Date:11/20/2009)...rch Center (ERC) has been awarded a grant from the...s of recovering and reusing the heat that would be...on process in a carbon capture system. The goal of...ure and sequestration, or storage (CCS), and thus ...ed into the atmosphere by coal-fired power plants....
(Date:11/19/2009)... chemical with an unwieldy name: 4-hydroxybutyrate...as a date-rape drug. , Now, a team of Ohio and ...which 4-HB is metabolized by the body. "This is ne...on, professor and chair of biological sciences at ...the research team. "It may provide new clues on h...
(Date:11/19/2009)... cultivate fungus for food, have many remarkable q...: the ant farmers, like their human counterparts, ...ardens grow. The finding, reported this week (Nov....sly unknown symbiosis between ants and bacteria an...come to dominate the American tropics and subtropi...
Breaking Biology News(10 mins):Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 3Researchers begin to decipher metabolism of sexual assault drug 2Like humans, ants use bacteria to make their gardens grow 2New 2009 Cumulative Supplement to Pharmaceutical Patent Law Examines Critical Intersection Of Patent Law and Food And Drug Law 59490 1New 2009 Cumulative Supplement to Pharmaceutical Patent Law Examines Critical Intersection Of Patent Law and Food And Drug Law 59490 2New 2009 Cumulative Supplement to Pharmaceutical Patent Law Examines Critical Intersection Of Patent Law and Food And Drug Law 59490 3American Academy of Physician Assistants Applauds Senate Finance Committee for Advancing Health Reform Legislation 59488 1American Academy of Physician Assistants Applauds Senate Finance Committee for Advancing Health Reform Legislation 59488 2New Fertility Financing Program for Donated Eggs Fills Void Left by Capital One 59486 1New Fertility Financing Program for Donated Eggs Fills Void Left by Capital One 59486 2
...sks of contracting a serious bacterial infection i...ion by the immune system causing destructive infla...t and other organ failure and death. Even the best...save patients stricken by severe sepsis. According...rs for Disease Control and Prevention, sepsis kill...
...ck Industries, Australian Animal Health Laboratory... Industries Victoria ?are investigating Koi herpes...h. , Project leader Dr Mark Crane says the virus,...ss mortalities in carp in the US, the UK, Israel, ...irus does not appear to have reached Australia. ,...
...esulting from HIV infection can lead to trouble wh...w study appearing in the Oct. 1 issue of The Journ... "Our study demonstrates that HIV-1 infected patie...ildren and pregnant women, an additional vulnerabl...yden, MD, MSc, lead author of the article. , CD...
Other Biology News:Researchers identify new weapon to fight deadly bacterial sepsis 2Researchers identify new weapon to fight deadly bacterial sepsis 3Virus may control Australia's 2Malaria treatment efficacy compromised in certain HIV-positive patients 2
Rabbit Anti-Human IFN-Alpha / Beta R2 (IFNAR2) (CD118) Neutralizing Polyclonal Antibody, Unconjugated from PBL InterferonSource
ImageQuant 400 from GE Healthcare, formerly Amersham Biosciences
ImageQuant 100 UV from GE Healthcare, formerly Amersham Biosciences
IMAGEQUANT 300 IQTL from GE Healthcare, formerly Amersham Biosciences
Biology Products: